Advertisement

Topics

Chiesi Group Company Profile

12:27 EST 10th December 2018 | BioPortfolio

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research centres, the Group has over 2,700 employees, of whom 300 are involved in research and development activities.

Chiesi’s technologies and products are available in over 50 countries through a strategic alliances network of international pharmaceutical groups developed both on a global and local scale. Group turnover reached 565 million Euros in 2005. Historically, the continuous development of the Company has been based on strategic planning for innovation, internationalisation, socially compatible economical values, and use of effective organizational structures.

Chiesi's formula for success is based on a peculiar approach that allows to combine factors often thought of as opposites in the pharmaceutical industry – such as research and ethics, technology and humanity, commitment to results and concern for individuals, reliability and empathy – while encouraging innovation at all levels. The final goal is the creation of value through innovation.

Location

Chiesi Farmaceutici S.p.A.Via Palermo, 26/A,
Parma
43100
Italy

Contact

Phone: 39 0521 2791
Fax: 39 0521 774468
Email: info@chiesigroup.com


News Articles [679 Associated News Articles listed on BioPortfolio]

Chiesi, new partner in d·HEALTH Barcelona program

Chiesi, new partner in d·HEALTH Barcelona program28.05.2018

Chiesi Gains U.S. Rights to Protalix' Phase III Fabry Disease Candidate PRX-102

Protalix BioTherapeutics said today it has granted Chiesi Farmaceutici exclusive U.S. rights to develop and commercialize the Phase III Fabry disease treatment PRX-102 (pegunigalsidase alfa), in an ex...

StartUp Health closes new $31 million fund focused on ‘health moonshots’

The investment vehicle is backed by major pharma companies like Novartis, Otsuka and the Chiesi Group, along with Irvine-based

Chiesi's limbal stem cell deficiency drug gets FDA orphan status

Limbal stem cell deficiency drug candidate GPLSCD01 from Chiesi USA received orphan drug status from the FDA. -More- 

NICE does not recommend Chiesi's Lamzede for alpha-mannosidosis

Rounds Report: Protalix And Chiesi Expanded The PRX-102 Partnership To Cover U.S. Territories

Holoclar® - The first stem-cell therapy approved for medical use in Europe

Dr Andreas Chiesi, CEO, Holostem Terapie Avanzate S.r.l

CENTOGENE and Chiesi Germany Sign Strategic Alliance in Lysosomal Storage Disorders

CENTOGENE to perform epidemiology study in Alpha Mannosidosis to support Chiesi’s drug discovery and development CENTOGENE and Chiesi Germany today announced a...

PubMed Articles [1744 Associated PubMed Articles listed on BioPortfolio]

Does Timing of Surgery Affect Treatment of the Terrible Triad of the Elbow?

BACKGROUND This study investigated the influence of surgical timing on the treatment of terrible triad of the elbow (TTE). MATERIAL AND METHODS After exclusion, 63 patients were enrolled in this study...

Isolation and exploitation of minority: Game theoretical analysis.

We investigate various group-size distributions occurring in a situation where each group's resource is exposed to appropriation by other groups. The amount of appropriation depends on the size differ...

Group I introns are widespread in archaea.

Group I catalytic introns have been found in bacterial, viral, organellar, and some eukaryotic genomes, but not in archaea. All known archaeal introns are bulge-helix-bulge (BHB) introns, with the exc...

The role of group cohesion in a group-based behavioral weight loss intervention.

Behavioral weight loss interventions are often delivered in groups. Group cohesion may enhance program attendance and, thereby, weight loss. In this secondary analysis, our goals were to: (1a) assess ...

Experimental animal study of docetaxel combined with carboplatin in the treatment of retinoblastoma.

The synergistic effects of docetaxel (DTX) combined with carboplatin in the treatment of retinoblastoma (RB) was explored in mouse RB xenografts compared with carboplatin alone and DTX alone groups. R...

Clinical Trials [4105 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...

The Influence of Hypotensive Drugs on Mineral Status in Experimental and Clinical Studies

The aim of the study was to evaluate the effects of hypotensive treatment combined with a higher zinc supply in the diet and supplements on the mineral status and selected biochemical para...

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Ultrasound and Exercises in Knee Osteoarthritis

The aim of this investigation is to compare the effects of continuous (CUS) and pulsed (PUS) ultrasound associated with a program of exercises on pain, range of motion, muscle strength, fu...

Technical Development of Multi-Parametric Renocerebral MRI

The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...

Companies [1640 Associated Companies listed on BioPortfolio]

Chiesi Group

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research ...

Chiesi Farmaceutici S.p.A.

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 ...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

ACE Group

Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...

More Information about "Chiesi Group" on BioPortfolio

We have published hundreds of Chiesi Group news stories on BioPortfolio along with dozens of Chiesi Group Clinical Trials and PubMed Articles about Chiesi Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiesi Group Companies in our database. You can also find out about relevant Chiesi Group Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Bioethics
Bioethics is the study of controversial ethics brought about by advances in biology and medicine. Bioethicists are concerned with the ethical questions that arise in the relationships among life sciences, biotechnology, medicine, politics, law, and philo...


Corporate Database Quicklinks



Searches Linking to this Company Record